Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518945 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
A Phase 3 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT02518945 is a Phase 3 study that has completed, run by University at Buffalo. The registered enrollment target is 26 participants.
The verdict
NCT02518945, a Phase 3 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction.
Interventions
- DRUG Liraglutide
- DRUG Insulin
- DRUG Dapagliflozin
- DRUG Dapagliflozin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02518945
The ClinicalTrials.gov registry entry for NCT02518945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Liraglutide is the first listed.
NCT02518945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02518945 about?
NCT02518945 is a clinical study titled "Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes". This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic co...
What is the current status of trial NCT02518945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2015-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02518945?
The interventions under investigation include: Liraglutide (DRUG), Insulin (DRUG), Dapagliflozin (DRUG), Dapagliflozin placebo (DRUG).
Who is sponsoring clinical trial NCT02518945?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.